Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies

NCT04787042 is registered in ClinicalTrials.gov with Simcha IL-18, Inc. as lead sponsor.

NCT NCT04787042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04787042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies
Lead sponsor
Simcha IL-18, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 6, 2021
Completion date
December 31, 2025
Enrollment
316 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, carcinoma, melanoma, msi-high, non small cell lung cancer, renal cell carcinoma, solid tumor, squamous cell carcinoma of the head and neck, triple-negative breast cancer